Navigation Links
Avanir Pharmaceuticals to Present at Three Conferences in March
Date:2/23/2011

ALISO VIEJO, Calif., Feb. 23, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) today announced that company management will present an overview of the company at the following conferences in March.

  • Citi 2011 Global Healthcare Conference
    • Location: Hilton New York, New York, NY
    • Presentation date: Tuesday March 1, 2011
    • Presentation time: 8:00am ET

  • Cowen & Company Healthcare Conference
    • Location: Boston Marriott, Boston, MA
    • Presentation date: Tuesday March 8, 2011
    • Presentation time: 8:45am ET

  • 2011 Roth OC Growth Conference
    • Location: The Ritz Carlton, Laguna Niguel, CA
    • Presentation date: Monday March 14, 2011
    • Presentation time: 5:00pm PT

A live webcast and 30-day archive of these presentations will be available at http://www.avanir.com.

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR™ and NUEDEXTA™ are trademarks owned by Avanir Pharmaceuticals, Inc.

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.


'/>"/>
SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... 30, 2014 AutoTex PINK ... iconic pink ribbon in support of breast cancer awareness ... for businesses and non-profits to “go pink” -- supporting ... AutoTex PINK is a woman-owned company that is among ... are committed to partnering with their customers to raise ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Teeth replacement ... Dental Art Institute in Oxnard and Thousand Oaks, Calif., ... and tomorrow to provide training on full mouth rehabilitation. ... work, placing implants, providing cosmetic dentistry, correcting bite issues, ... said. , Dr. Jivraj, who has traveled to India ...
(Date:9/30/2014)... Loffler Companies, an award winning and ... was recognized by BEI as the number one ... This prestigious rating means that Loffler Service Technicians ... an extended period following, optimizing user productivity and ... Services has been the trusted provider for unbiased ...
(Date:9/30/2014)... CA (PRWEB) September 30, 2014 In ... commemorate breast cancer survivors and their courageous battles, Incredible ... to start afresh with PicoSure® by Cynosure. , ... blue or black tattoo is applied on their skin ... explains Dr. Sam Ebrahimi. “For many survivors, they decide ...
(Date:9/30/2014)... New York (PRWEB) September 30, 2014 ... Co-Founder of Hudson Allergy , will discuss how ... food allergies and other special dietary restrictions at the ... Restaurateurs & Food Service Professionals, October 21 in New ... on this incredibly important topic to such an engaged ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 2Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 3Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 4Health News:World-Renowned Dental Implant Expert, International Instructor in India Speaking about Reconstructive Dentistry 5Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 2Health News:Loffler Companies Rated Number One Among U.S. Dealers in Service “First Call Effectiveness” 3Health News:Incredible Veins, Body & Skin Takes A Stand Against Breast Cancer With PicoSure® By Cynosure 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 2Health News:Hudson Allergy’s Dr. Julie Kuriakose to Speak at Prestigious Food Allergy Conference in New York City 3
... in a precipitous decline, David C. Dale, MD, FACP, ... joined with leading representatives of employers and consumers ... recruit and retain general internists and other primary care ... state of primary care medicine in the U.S., Dr. ...
... Save Vital Services for Frail Seniors and People ... of,homecare workers across the state are outraged by ... wages and benefits,which would force some of California,s ... into poverty. They pledged to save these vital,services ...
... 10,000 Sensual O Condom Packs Donation Marks the Launch ... 16 On Saturday, May 17th 2008, hip-hop,and R & ... "Everybody in the Club,Gettin, Tipsy," will be presenting the Urban ... over $50,000. The donation is,being made to promote the launch ...
... who would benefit most from chemo after surgery, study says ... 15 genes may help determine which patients with early-stage non-small ... the most from chemotherapy, a new study shows. , ... with less aggressive forms of the cancer who would be ...
... tropical storms,continue to batter the affected area of ... to diseases and other severe problems. Many,survivors still ... and,malnutrition are creating an increasingly dire situation., ... more help to,recover from this disaster and get ...
... Research Funding Per Death Drops More in 2007, ... three cancer deaths, the National Cancer Institute (NCI) invested,less ... cancer research in 2007,according to updated statistics issued by ... federal agencies with significant cancer research,programs -- Centers for ...
Cached Medicine News:Health News:ACP says major system reforms needed to improve the state of primary care medicine in the US 2Health News:Homecare Workers Outraged by Proposed Cuts, Wage Reductions 2Health News:Everybody in the Club Scream O! 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2
... Elite II features a diagnostic ... of Glasgow,(UG) algorithm. Unlike competitive ... age, the UG,algorithm bases its ... gender, age, race, medication,and classification., ...
... test face is a LogMAR ... Landolt C in various orientations ... targets are presented at 10% ... useful for evaluating the low ...
The CSV-1000-1.5CPD is a special test face designed specifically for Food and Drug Administration clinical trials., ,At the recommended test distance of 8 feet, the gratings test one spatial frequenc...
... test face is used widely for screening ... LogMAR acuity from 20/10 to 20/100 and ... cycles/degree. , ,The patient can be easily ... acuity and contrast sensitivity. If a contrast ...
Medicine Products: